Diana B. R.
- Country
- France
- Department
- Service d'Oncologie Médicale
Research Overview
- De-escalation of endocrine therapy in postmenopausal women with low-risk HR+ HER2- low Luminal A early breast cancer: a single-arm study of omission versus combination therapy
- Phase 3 Randomized Study of Rinatabart Sesutecan + Bevacizumab vs Bevacizumab in Recurrent Platinum‑Sensitive Ovarian Cancer after Second‑Line Platinum Doublet
- Phase 2 Open‑Label Study of LY3484356 (imlunestrant) versus Tamoxifen or LY3484356 + Goserelin in Premenopausal ER‑Positive HER2‑Negative Early Breast Cancer
Data & Insights
Has run more than one trial at 154 of 356 partner sites.
Specializations
Gynecologic Oncology
The investigator specializes in treating advanced forms of gynecologic cancers, with particular emphasis on ovarian cancer, fallopian tube cancer, and primary peritoneal carcinoma.
- Platinum-resistant disease management
- High-grade epithelial cancers
- Peritoneal malignancies
Their research extends to innovative therapeutic approaches for patients with endometrial carcinoma and cervical cancer.
Targeted Therapies
The investigator focuses on developing and evaluating novel targeted treatments, including research into HER2-positive cancers and NRG1 fusion-positive tumors.
- Monoclonal antibody therapies
- Anti-HER2 targeted treatments
- Biomarker-driven approaches
Their work includes investigation of therapeutic de-escalation strategies and combination treatment protocols.
Advanced Solid Tumors
The investigator conducts research on various types of solid tumors, including hepatocellular carcinoma and colorectal cancer.
- Novel drug combinations
- Treatment optimization
- Disease progression monitoring
Their research encompasses both early and late-stage clinical development of innovative anticancer therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.